The initial findings from a small clinical trial of patients with multiple myeloma or sarcoma suggest that gene-edited immunotherapy is safe.

In demonstrations in cell lines, the technique has a similar efficacy to CRISPR-Cas9, but fewer off-target effects.

Genetically engineered Drosophila withstand toxins common in monarch butterflies’ diet.

The authors have requested a retraction of a paper that found people with the CCR5 Δ32 variant are more likely to die sooner.

Scientists injected unfertilized anole lizard eggs with CRISPR-Cas9 to produce albino offspring.

Genetic engineers have co-opted base editing machinery to enable information storage and processing in the DNA of bacterial and mammalian cells.

A trial is recruiting patients to test the gene-editing technology’s ability to treat an inherited form of blindness caused by a mutation in the CEP290 gene.

In the wake of reports of CRISPRed babies born in China, a bipartisan resolution “opposes the experiments that resulted in pregnancies using genome-edited human embryos.”

The US patent office declares an interference between the intellectual property held by the Broad Institute and several patent applications filed by the University of California—opposite its previous ruling.